ABCL 8-K 2026-11-09

AbCellera Biologics Inc. (ABCL) 8-K dated 2026-11-09 — accession 0001703057-26-000058.

AbCellera Biologics Inc. (ABCL) is a biotechnology company listed on US.

ABCL revenue $10.6M

This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ABCL revenue for 2025-12-31 was $75.1M. Net income was -$146.4M. Revenue was up 160.6% from 2024-12-31 to 2025-12-31. ABCL currently screens at market cap $1.12B.

Not investment advice. The ABCL SEC hub lists recent forms. The stock page is the research view.